Mouse Anti-LMO3 Recombinant Antibody (1A8) (CBMAB-A5021-LY)

Ohara, Y., Craig, A. J., Liu, H., Yang, S., Moreno, P., Dorsey, T. H., ... & Hussain, S. P. (2023). LMO3 is a suppressor of the basal-like/squamous PDAC subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism. bioRxiv, 2023-11.

Ling, Z., Long, X., Wu, Y., Li, J., & Feng, M. (2022). LMO3 promotes proliferation and metastasis of papillary thyroid carcinoma cells by regulating LIMK1-mediated cofilin and the β-catenin pathway. Open Medicine, 17(1), 453-462.

Wagner, G., Fenzl, A., Lindroos-Christensen, J., Einwallner, E., Husa, J., Witzeneder, N., ... & Bilban, M. (2021). LMO3 reprograms visceral adipocyte metabolism during obesity. Journal of Molecular Medicine, 99(8), 1151-1171.

Savarese, A., & Lasek, A. W. (2018). Regulation of anxiety-like behavior and Crhr1 expression in the basolateral amygdala by LMO3. Psychoneuroendocrinology, 92, 13-20.

Qiu, Y. S., Jiang, N. N., Zhou, Y., Yu, K. Y., Gong, H. Y., & Liao, G. J. (2018). LMO3 promotes gastric cancer cell invasion and proliferation through Akt-mTOR and Akt-GSK3β signaling. International journal of molecular medicine, 41(5), 2755-2763.

Cheng, Y., Hou, T., Ping, J., Chen, T., & Yin, B. (2018). LMO3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with LATS1 and suppressing Hippo signaling. Journal of Experimental & Clinical Cancer Research, 37(1), 1-12.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols